Enda Byrne
Senior Research Fellow
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Twin studies reveal high genetic overlap between anxiety disorders and depression, contributing to the internalising spectrum. Some genetic specificity for fear-based anxiety disorders (fear), distinct from general anxiety and depression (distress), has also emerged. Limited datasets with detailed phenotyping across anxiety disorders have restricted most genome-wide association studies (GWAS) to “any anxiety diagnosis”. Additional genome-wide evidence to discern genetic differences between fear and distress is required. We conducted GWAS meta-analyses of fear (panic, agoraphobia, specific phobia, social anxiety disorder) and generalised anxiety disorder (GAD), measured using brief single-item and detailed symptom-based diagnoses from three datasets. We explored two control group criteria: phenotype-specific (fear/GAD) or broader anxiety/depression screening. We identified one SNP-based independent locus and three gene-level genome-wide significant (GWS) associations with fear (up to 35,523 N cases ; 157,447 N controls ). Four GWS SNP-based loci and three gene-level loci were associated with GAD (up to 60,879 N cases ; 117,064 N controls ). The genetic correlation between fear and GAD was significantly different from unity only when excluding a depression-enriched dataset and using phenotype-specific control screening (r g = 0.87; P = 9.32 × 10 −3 ). Most complex traits had statistically similar genetic correlations with fear and GAD, including depression. Exceptions included general cognitive ability, educational attainment, and coronary artery disease, showing statistically stronger genetic correlations with fear than GAD, while bipolar disorder type I, anorexia nervosa, and neuroticism displayed the opposite pattern. Our findings partially support a distress-fear genetic distinction, but show stronger evidence for an overarching genetic liability to internalising psychopathology driving comorbidity across anxiety disorders and depression.
Year:
2026
There are striking sex differences in the prevalence and symptomology of Major Depressive Disorder. Here, we conduct the largest sex-stratified genome wide association and genotype-by-sex interaction meta-analyses of Major Depressive Disorder to date (Females: 130,471 cases, 159,521 controls. Males: 64,805 cases, 132,185 controls). We identify 16 and eight independent genome-wide significant variants in females and males, respectively, including one novel variant on the X chromosome. Major Depressive Disorder in females and males shows substantial genetic overlap with a large proportion of variants displaying similar effect sizes across sexes. However, we also provide evidence for a higher burden of genetic risk in females which could be due to female-specific variants. Additionally, sex-specific pleiotropic effects may contribute to the higher prevalence of metabolic symptoms in females with Major Depressive Disorder. These findings underscore the importance of considering sex-specific genetic architectures in the study of health conditions, including Major Depressive Disorder, paving the way for more targeted treatment strategies.
Year:
2025
Background Increasing daylight exposure might be a simple way to improve mental health. However, little is known about daylight-symptom associations in depressive disorders. Methods In a subset of the Australian Genetics of Depression Study ( N = 13,480; 75% female), we explored associations between self-reported number of hours spent in daylight on a typical workday and free day and seven symptom dimensions: depressive (overall, somatic, psychological); hypo-manic-like; psychotic-like; insomnia; and daytime sleepiness. Polygenic scores for major depressive disorder (MDD); bipolar disorder (BD); and schizophrenia (SCZ) were calculated. Models were adjusted for age, sex, shift work status, employment status, season, and educational attainment. Exploratory analyses examined age-stratified associations (18–24 years; 25–34 years; 35–64 years; 65 and older). Bonferroni-corrected associations ( p < 0.004) are discussed. Results Adults with depression reported spending a median of one hour in daylight on workdays and three hours on free days. More daylight exposure on workdays and free days was associated with lower depressive (overall, psychological, somatic) and insomnia symptoms ( p ’s<0.001), but higher hypo-manic-like symptoms ( p ’s<0.002). Genetic loading for MDD and SCZ were associated with less daylight exposure in unadjusted correlational analyses (effect sizes were not meaningful). Exploratory analyses revealed age-related heterogeneity. Among 18–24-year-olds, no symptom dimensions were associated with daylight. By contrast, for the older age groups, there was a pattern of more daylight exposure and lower insomnia symptoms ( p < 0.003) (except for 25–34-year-olds on free days, p = 0.019); and lower depressive symptoms with more daylight on free days, and to some extent workdays (depending on the age-group). Conclusions Exploration of the causal status of daylight in depression is warranted.
Year:
2025
Year:
2025
Importance Antidepressant treatment remains largely trial-and-error, with approximately one-third of patients with major depressive disorder (MDD) reporting inefficacy of first-line medications. Identifying predictors of treatment acceptability is needed to improve prescribing precision and patient outcomes. Objective To identify phenotypic and genetic signatures associated with antidepressant acceptability and treatment complexity. Design, Setting, and Participants Retrospective cohort study of Australian Genetics of Depression Study participants dispensing ≥1 prescription of the 10 most commonly used antidepressants, based on linked 4.5-year (2013–2017) prescription data. Exposures Treatment complexity was assessed as number of antidepressant classes dispensed. Antidepressant acceptability was defined as sustained single-antidepressant use (≥360 cumulative days). Participants with genotyping data were classified into mutually exclusive groups based on sustained single-medication use. Main Outcomes and Measures Associations with 40 phenotypes and polygenic scores (PGS) for 15 traits. Genome-wide association studies (GWAS) were conducted for SSRI and SSRI/SNRI antidepressant acceptability. Results Of 13,763 participants with ≥1 antidepressant prescription, 9,844 had genotyping data (mean [SD] age 44.5 [15.0] years; 26% male; 89% lifetime MDD). Treatment complexity was significantly associated with 27 of 40 phenotypes (e.g., smoking, recurrent MDD, suicidal ideation, chronic pain, BMI) and higher PGSs for psychiatric traits (MDD, ADHD, bipolar disorder, neuroticism; β = 0.028– 0.045 per PGS SD unit, p = 9.9 × 10 -6 to 2.1 × 10 -10 ). Sixty percent met criteria for an exclusive antidepressant acceptability group. These groups had distinct phenotypic profiles, including associations with BMI, suicidal ideation, and comorbidities. In particular, only SNRI users had higher BMI than SSRI users, but this association was explained by the BMI PGS, indicating genetic rather than treatment-induced differences. GWAS identified novel loci including an immune-related gene LY9 , for which the G allele of rs6427545 was associated with reduced SSRI acceptability (frequency = 0.31; OR = 0.82; p = 2.8 × 10 -8 ) Conclusions and Relevance Antidepressant acceptability and complex treatment patterns correspond to distinct phenotypic and genetic signatures. PGS demonstrate potential for enabling precision psychiatry, and immune-related pathways warrant therapeutic investigation. Key Points Question Can phenotypic and genetic factors help identify individuals likely to show antidepressant-specific acceptability and treatment complexity, improving treatment precision in major depressive disorder (MDD)? Findings In this cohort study of 13,763 individuals with antidepressant prescriptions, treatment complexity was associated with 27 self-reported phenotypic traits and higher polygenic scores (PGS) for psychiatric conditions. Among 9,844 genotyped participants, 60% met criteria for single-antidepressant acceptability, with distinct phenotypic and genetic profiles. Notably, higher BMI among sustained SNRI users was explained by genetic predisposition. A genome-wide association study identified novel loci, including an immune-related gene ( LY9 ), associated with reduced SSRI acceptability. Meaning Phenotypic and genetic factors, including PGS, are associated with both antidepressant acceptability and treatment complexity. These findings support the use of such markers to guide treatment selection and identify patients at risk for more complex courses, informing precision psychiatry and early intervention in MDD.
Year:
2025
Background Atypical depression is considered a distinct clinical subtype of major depression, yet its predictive validity and clinical utility remain contested. We investigated association between atypical depression and clinical characteristics, genetic profiles, and antidepressant responses. Methods Among 14,897 participants from the Australian Genetics of Depression Study (75% female; mean age 43.7 years), 3,098 (21%) were classified phenotypically as having “atypical depression” based on self-reported weight gain and hypersomnia during their worst depressive episode. Demographics and clinical features were compared. Bonferroni-corrected regression models assessed associations between atypical depression and polygenic scores (PGS) for mental disorders, metabolic-inflammatory-circadian traits, and self-reported antidepressant response and side effects. Results Atypical depression cases had an earlier age of onset, greater illness severity, stronger eveningness and reduced daylight exposure. Atypical depression cases had higher PGS for major depressive disorder (odds ratio [OR]=1.10 [95%CI: 1.06-1.15]), attention-deficit/hyperactivity disorder (OR=1.08 [1.04-1.13]), bipolar disorder (OR= 1.07 [1.02-1.12]), neuroticism (OR=1.07 [1.02-1.12]), BMI (OR=1.35 [1.29-1.42]), Type 2 diabetes (OR=1.22 [1.16-1.28]), C-reactive protein (OR=1.12 [1.07-1.17]), and insulin resistance (OR=1.11 [1.06-1.16]) but lower PGS for HDL cholesterol (OR=0.91 [0.87-0.95]) and chronotype (indicating eveningness; OR=0.94 [0.90-0.98]). Atypical depression was associated with poorer efficacy of selective serotonin reuptake inhibitors (OR=0.88 [0.81-0.96]) and serotonin-norepinephrine reuptake inhibitors (OR=0.85 [0.77-0.94]), along with more side effects, particularly weight gain (OR=2.89 [2.66-3.15]). Conclusions This large genetically-informative study supports the neurobiological and clinical validity of atypical depression, demonstrating distinct clinical and genetic risk profiles alongside differential antidepressant responses. These support utilizing the atypical subtype to guide treatment selection and physical health management.
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Collaborators (64)
Mirim Shin
University of Sydney
Harold Snieder
Scientific Staff
University Medical Center Groningen
Naomi Wray
University of Queensland
Sue Cotton
Professor
MONASH UNIVERSITY
Sang hyuck Lee
King’s College London
Monika McAtarsney-Kovacs
Anglia Ruskin University
Ian Jones
Director National Centre for Mental Health, Professor of Psychiatry
Cardiff University
Alex Kwong
Academic , Senior Research Associate
University of Bristol
Gerome Breen
Professor of Psychiatric Genetics
King’s College London
Nathan Skene
Associate Professor and UK DRI Group Leader
Imperial College London
Clara Albiñana
Aarhus University
Nicholas Timpson
Academic , Professor of Genetic Epidemiology
University of Bristol
Andrew McIntosh
Professor of Biological Psychiatry
University of Edinburgh
Alexandra Havdahl
Prof
Norwegian Institute of Public Health
Chloe Yap
Clinical Researcher
University of Oxford
Matthew Hotopf
South London and Maudsley NHS Foundation Trust
Cherie Armour
The Queen's University Belfast
Serena Sanna
Scientific Staff
University Medical Center Groningen
Colette Hirsch
Professor of Cognitive Clinical Psychology
King’s College London
Maxime Taquet
Associate Professor
University of Oxford
Albertine J. Oldehinkel
Scientific Staff, Professor
University Medical Center Groningen
F. Huider
University of Amsterdam
Daniel Adkins
Full Professor
University of Utah
Brittany Mitchell
Senior Research Fellow
QIMR Berghofer Medical Research Institute
Iiris Hovatta
University of Helsinki
Alan Murphy
Imperial College London
Lianne Schmaal
Professor
University of Melbourne
Juergen Hoyer
Professor
-
Catharina A. Hartman
-
Evangelos Vassos
Clinical Reader
King’s College London
Anna Elisabeth Fürtjes
Research Associate in Statistical Genetics
University of Edinburgh
James Walters
Director and Clinical Professor
Cardiff University
Sarah Medland
QIMR Berghofer Medical Research Institute
Donald M. Lyall
-
David Whiteman
Deputy Director
QIMR Berghofer Medical Research Institute
Nathalie Kingston
Research Professor
University of Cambridge
Michelle Lupton
Team Head
QIMR Berghofer Medical Research Institute
Shin Ho Park
University of Sydney
Jan Richter
University of Hildesheim
Michela Noseda
Imperial College London
Geneviève Morneau-Vaillancourt
Professeure adjointe
Université de Sherbrooke
Nicholas Martin
Senior Scientist and Senior Principal Research Fellow
QIMR Berghofer Medical Research Institute
Mary-Ellen Lynall
Clinical Lecturer
University of Cambridge
Christel Middeldorp
Professor
-
Andrea Cipriani
Director
University of Oxford
Daniel J Smith
Chair of Psychiatry
University of Edinburgh
Jacob J. Crouse
University of Sydney
Elham Assary
King’s College London
Cisca Wijmenga
Lodewijk Sandkuijl distinguished university professor of human genetics
University Medical Center Groningen
Miguel Garcia-Argibay
University of Southampton
Ian B. Hickie
Co-Director Health and Policy
University of Sydney
Christopher Hübel
VIP, Researcher
Aarhus University
Catherine Olsen
QIMR Berghofer Medical Research Institute
Jonathan Coleman
Senior Lecturer in Statistical Genetics
King’s College London
Teemu Palviainen
University of Helsinki
Georg W. Alpers
University of Mannheim
Jaakko Kaprio
Research Director
University of Helsinki
Thalia Eley
Professor of Developmental Behavioural Genetics
King’s College London
Roland Zahn
King’s College London
Peter Koval
Professor
University of Melbourne
Johan Zvrskovec
Karolinska Institutet
Simon Rice
Associate Professor
University of Melbourne
Saakshi Kakar
King's College London
Molly Davies
King’s College London
Make your next move.
Prepare your application
Review drafts before you send them.